ISSX Webinar: Ozanimod Metabolism – Qualification of Disproportionate Metabolites
Presented by Sekhar Surapaneni, Ph.D.
Thursday, October 1 at 11:00 am ET US
Non-Member Registration Member Registration
Ozanimod is a once-daily oral immunomodulator that selectively targets sphingosine 1-phosphate 1 (S1P1) and S1P5 and is approved in the US and EU for the treatment of relapsing forms of multiple sclerosis. Full characterization of drug metabolic pathways and enzymes involved in metabolism is important for understanding clinical safety and efficacy profile of the molecule. In vitro and in vivo studies were conducted to characterize the metabolism and identify the pathways and enzymes involved in the metabolism. The unique metabolic aspects of ozanimod and characterization and qualification of disproportionate metabolites in safety species will be discussed.
About the Speaker:
||Sekhar Surapaneni is currently Vice President, Nonclinical Disposition and Bioanalysis, BMS and his group is responsible for conducting all drug metabolism and bioanalytical studies in support of drug development for small molecules, biologics and cellular therapies. Prior to joining BMS, he has about 25 years of experience in drug metabolism and pharmacokinetics area working at Lilly, Abbott, Amgen and Celgene. He received undergraduate training in Pharmacy from BITS, Pilani, India, and PhD in Pharmaceutical Sciences from North Dakota State University.